RRML - Genotype-phenotype correlations in patients treated with acenocoumarol
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2020): 1.027

Rejection rate (2020): 75%

Română English


Clarivate analytics (ISI) Impact factor


Advanced search


Top 10 downloaded articles
- September 2021 -
 
Insights into Innate Immune Re... 22
Correction factor between two ... 13
The effects of microwave radia... 10
The Expression of miR-155-5p a... 9
Genetic Diagnostic Approaches ... 7
Romanian Review of Laboratory ... 6
Essentials in the diagnosis of... 6
Atellica CH 930 chemistry anal... 6
Molecular diagnostic of Ureapl... 5
Prognostic value of serum lact... 5

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 22(3)/2014 DOI:10.2478/rrlm-2014-0032
XML
TXT

Genotype-phenotype correlations in patients treated with acenocoumarol

Florentina Claudia Militaru, Ștefan Cristian Vesa, Sorin Crișan, Valentin Militaru, Adrian Pavel Trifa, Anca Dana Buzoianu


Abstract:

Aim: This research aims to establish a genotype-phenotype correlation in patients treated with acenocoumarol and studies the genetic factors (VKORC1 and CYP2C9 polymorphisms) that may influence INR values during initiation of oral anticoagulant therapy with acenocoumarol. Material and methods: We included 131 patients that needed treatment with acenocoumarol, 70 (53.4%) women and 61 (46.6%) men, observed at the 5th Medical Clinic in Cluj-Napoca, between 2009-2011. We studied the influence of age, gender, concomitant medication and of CYP2C9 and VKORC1 genes on the INR value recorded on the third day of treatment and on the difference between this value and the initial INR value at the starting point for the treatment (INRDIF). Results and conclusion: We demonstrated a statistically significant difference for INR3 and INRDIF values in patients with AA genotype and those with GG genotype of the c.-1639G>A polymorphism of the VKORC1 gene. The presence of AA genotype of the c.-1639G>A polymorphism of the VKORC1 gene determined a 15.7-fold increase in the risk that a patient might display supratherapeutic INR after 2 days of treatment with 4 mg of acenocoumarol.

Keywords: Acenocoumarol, CYP2C9, INR, VKORC1

Received: 13.5.2014
Accepted: 10.8.2014
Published: 2.9.2014

 
  PDF Download full text PDF
(286 KB)
     
 
How to cite
Militaru FC, Vesa ȘC, Crișan S, Militaru V, Trifa AP, Buzoianu AD. Genotype-phenotype correlations in patients treated with acenocoumarol. Rev Romana Med Lab. 2014;22(3):347-54. DOI:10.2478/rrlm-2014-0032